Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries....
Main Authors: | Arnaud Boyer, Eddy Pasquier, Pascale Tomasini, Joseph Ciccolini, Laurent Greillier, Nicolas Andre, Fabrice Barlesi, Celine Mascaux |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2018-03-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/27/147/170098.full |
Similar Items
-
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes
by: Pascale Tomasini, et al.
Published: (2016-05-01) -
Personalised medicine for nonsmall cell lung cancer
by: Céline Mascaux, et al.
Published: (2017-11-01) -
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
by: Bernard Staumont, et al.
Published: (2020-06-01) -
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
by: Laurent Greillier, et al.
Published: (2016-10-01) -
Immunotherapy in Malignant Pleural Mesothelioma
by: Cornedine J. de Gooijer, et al.
Published: (2020-02-01)